This template was built with Webflow's free Prospero UI Kit. Learn more
If your child has recently been diagnosed with an SCN2A-related disorder — or if you are still in the process of getting answers — you may be searching for one thing above everything else: understanding. What will my child experience? Why does this look so different from what another family is going through? Is there anything we can do?
These are the right questions. And you deserve clear, honest answers.
SCN2A symptoms can look very different from one child to the next. That is not an accident — it is a direct reflection of the specific genetic change your child carries. This guide walks through the most common symptoms, explains why such wide variation exists, and helps you understand how mutation type plays a central role in shaping your child’s experience.
The SCN2A gene provides the instructions for building a protein called Nav1.2 — a sodium channel found primarily in the brain. Sodium channels act like tiny gates, opening briefly to allow sodium ions into nerve cells. This process generates the electrical signals that allow brain cells to communicate.
When the SCN2A gene carries a pathogenic variant (a disease-causing mutation), the Nav1.2 channel does not work as it should. Depending on the specific variant, the channel may become overactive, underactive, or unpredictably dysregulated. To learn more about what SCN2A is and how it affects the brain, visit our full overview page.
SCN2A-related disorders span a wide spectrum. Some children experience severe, early-onset epilepsy beginning within the first days of life. Others may have no seizures at all but face significant developmental and behavioral challenges. Some children sit somewhere in between.
This variability is not random. Research has shown a strong relationship between the specific SCN2A variant a child carries and the nature of their symptoms — a concept called genotype-phenotype correlation. In practical terms, this means that understanding your child’s mutation type is one of the most important steps toward understanding their individual symptom profile.
Seizures are among the most commonly recognized symptoms of SCN2A-related disorders, though they do not occur in every individual. When present, seizures can range widely — from brief focal episodes to prolonged, difficult-to-treat convulsions. They may begin within the first days of life, in early infancy, or not until later childhood.
Some children are also diagnosed with specific epilepsy syndromes such as West syndrome, Ohtahara syndrome, or epilepsy of infancy with migrating focal seizures (EIMFS), based on the types of seizures they experience.
It is important to know that a number of children with SCN2A-related disorders never develop epilepsy at all. In those cases, neurodevelopmental symptoms — not seizures — are the primary presentation.
Many children with SCN2A-related disorders experience developmental delay — reaching milestones in sitting, walking, talking, and learning later than expected. For some children, delays are mild. For others, they are more significant. Intellectual disability can also be present, ranging from mild to profound, and is more common in children with de novo (not inherited) variants.
SCN2A is recognized as a high-confidence risk gene for autism spectrum disorder (ASD). Many children with SCN2A variants — particularly those with loss-of-function mutations — display features associated with ASD, including challenges with social communication, sensory sensitivities, and a preference for routine. In some children, an ASD diagnosis comes before an epilepsy diagnosis, or in place of one entirely.
Movement disorders are an underappreciated but significant part of the SCN2A symptom picture. These may include hypotonia (low muscle tone, sometimes described as “floppiness”), ataxia (uncoordinated movement), dyskinesia (abnormal involuntary movements), and dystonia (muscle stiffening or contractions). These symptoms can appear alongside epilepsy or as a primary concern in children without seizures.
Many families are surprised to learn that SCN2A-related disorders can affect systems beyond the brain — including the gut. Because the nervous system governs gastrointestinal function, Nav1.2 dysfunction can lead to constipation, gastroesophageal reflux, diarrhea, and in more severe cases, gastrointestinal dysmotility (difficulty moving food through the digestive tract). Feeding difficulties are also common, particularly in young children.
Some children also experience sleep disturbances and symptoms related to autonomic nervous system dysfunction, such as difficulty with temperature regulation.
This is where the SCN2A story becomes especially important for families to understand — and where the Foundation’s educational mission focuses closely.
Gain-of-function (GOF) variants cause the Nav1.2 channel to become overactive, allowing too much sodium to flow into neurons. This excess electrical activity is typically associated with severe, early-onset epilepsy beginning before 3 months of age. Seizures in GOF presentations often require careful medical management, and a child’s treatment team will typically focus heavily on seizure control.
The latest SCN2A research advancing today is helping to better define how GOF variants affect the developing brain and which therapeutic approaches show the most promise.
Loss-of-function (LOF) variants reduce or eliminate Nav1.2 channel activity, resulting in neurons that cannot signal properly. This is the most common variant type — accounting for roughly 80% of pathogenic SCN2A variants. LOF variants are more commonly associated with ASD, intellectual disability, and developmental delay, and when seizures occur, they tend to appear later — typically after 3 months of age.
It is critical for families and clinicians to know that certain seizure medications that work well for GOF presentations may not be appropriate — and can actually worsen symptoms — in children with LOF variants. Always work with a neurologist experienced in SCN2A-related disorders to guide treatment decisions.
Mixed function SCN2A variants are an increasingly recognized third category. These variants produce a combination of gain- and loss-of-function effects on the Nav1.2 channel — some electrophysiological measurements show overactivity, while others show underactivity. The result is a symptom profile that does not fit neatly into either the GOF or LOF category.
Children with mixed function variants may experience both epilepsy and neurodevelopmental features, and their responses to treatment can be less predictable. For families navigating a mixed function diagnosis, specialist involvement and individualized care planning are especially important. The SCN2A research community is actively working to better characterize these variants and their treatment implications.
The age at which symptoms — particularly seizures — first appear is one of the most informative clues about the underlying variant type. Seizures appearing within the first days or weeks of life most often reflect GOF variants. Seizures appearing after 3 months of age, or developmental and behavioral concerns emerging without prominent epilepsy, are more commonly associated with LOF or mixed function variants.
That said, timing alone does not determine mutation type. Genetic testing remains the only definitive way to identify the specific SCN2A variant your child carries and begin to understand its functional implications.
If your child has been diagnosed with an SCN2A-related disorder, or if you recognize these symptoms and have not yet received a genetic diagnosis, you are not alone — and there are steps you can take.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
Want to go further? Join the fight to stay connected to the latest SCN2A research and advocacy efforts, or contact us with any questions.
Medical Disclaimer
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Share
If your child has recently been diagnosed with an SCN2A-related disorder — or if you are still in the process of getting answers — you may be searching for one thing above everything else: understanding. What will my child experience? Why does this look so different from what another family is going through? Is there anything we can do?
These are the right questions. And you deserve clear, honest answers.
SCN2A symptoms can look very different from one child to the next. That is not an accident — it is a direct reflection of the specific genetic change your child carries. This guide walks through the most common symptoms, explains why such wide variation exists, and helps you understand how mutation type plays a central role in shaping your child’s experience.
The SCN2A gene provides the instructions for building a protein called Nav1.2 — a sodium channel found primarily in the brain. Sodium channels act like tiny gates, opening briefly to allow sodium ions into nerve cells. This process generates the electrical signals that allow brain cells to communicate.
When the SCN2A gene carries a pathogenic variant (a disease-causing mutation), the Nav1.2 channel does not work as it should. Depending on the specific variant, the channel may become overactive, underactive, or unpredictably dysregulated. To learn more about what SCN2A is and how it affects the brain, visit our full overview page.
SCN2A-related disorders span a wide spectrum. Some children experience severe, early-onset epilepsy beginning within the first days of life. Others may have no seizures at all but face significant developmental and behavioral challenges. Some children sit somewhere in between.
This variability is not random. Research has shown a strong relationship between the specific SCN2A variant a child carries and the nature of their symptoms — a concept called genotype-phenotype correlation. In practical terms, this means that understanding your child’s mutation type is one of the most important steps toward understanding their individual symptom profile.
Seizures are among the most commonly recognized symptoms of SCN2A-related disorders, though they do not occur in every individual. When present, seizures can range widely — from brief focal episodes to prolonged, difficult-to-treat convulsions. They may begin within the first days of life, in early infancy, or not until later childhood.
Some children are also diagnosed with specific epilepsy syndromes such as West syndrome, Ohtahara syndrome, or epilepsy of infancy with migrating focal seizures (EIMFS), based on the types of seizures they experience.
It is important to know that a number of children with SCN2A-related disorders never develop epilepsy at all. In those cases, neurodevelopmental symptoms — not seizures — are the primary presentation.
Many children with SCN2A-related disorders experience developmental delay — reaching milestones in sitting, walking, talking, and learning later than expected. For some children, delays are mild. For others, they are more significant. Intellectual disability can also be present, ranging from mild to profound, and is more common in children with de novo (not inherited) variants.
SCN2A is recognized as a high-confidence risk gene for autism spectrum disorder (ASD). Many children with SCN2A variants — particularly those with loss-of-function mutations — display features associated with ASD, including challenges with social communication, sensory sensitivities, and a preference for routine. In some children, an ASD diagnosis comes before an epilepsy diagnosis, or in place of one entirely.
Movement disorders are an underappreciated but significant part of the SCN2A symptom picture. These may include hypotonia (low muscle tone, sometimes described as “floppiness”), ataxia (uncoordinated movement), dyskinesia (abnormal involuntary movements), and dystonia (muscle stiffening or contractions). These symptoms can appear alongside epilepsy or as a primary concern in children without seizures.
Many families are surprised to learn that SCN2A-related disorders can affect systems beyond the brain — including the gut. Because the nervous system governs gastrointestinal function, Nav1.2 dysfunction can lead to constipation, gastroesophageal reflux, diarrhea, and in more severe cases, gastrointestinal dysmotility (difficulty moving food through the digestive tract). Feeding difficulties are also common, particularly in young children.
Some children also experience sleep disturbances and symptoms related to autonomic nervous system dysfunction, such as difficulty with temperature regulation.
This is where the SCN2A story becomes especially important for families to understand — and where the Foundation’s educational mission focuses closely.
Gain-of-function (GOF) variants cause the Nav1.2 channel to become overactive, allowing too much sodium to flow into neurons. This excess electrical activity is typically associated with severe, early-onset epilepsy beginning before 3 months of age. Seizures in GOF presentations often require careful medical management, and a child’s treatment team will typically focus heavily on seizure control.
The latest SCN2A research advancing today is helping to better define how GOF variants affect the developing brain and which therapeutic approaches show the most promise.
Loss-of-function (LOF) variants reduce or eliminate Nav1.2 channel activity, resulting in neurons that cannot signal properly. This is the most common variant type — accounting for roughly 80% of pathogenic SCN2A variants. LOF variants are more commonly associated with ASD, intellectual disability, and developmental delay, and when seizures occur, they tend to appear later — typically after 3 months of age.
It is critical for families and clinicians to know that certain seizure medications that work well for GOF presentations may not be appropriate — and can actually worsen symptoms — in children with LOF variants. Always work with a neurologist experienced in SCN2A-related disorders to guide treatment decisions.
Mixed function SCN2A variants are an increasingly recognized third category. These variants produce a combination of gain- and loss-of-function effects on the Nav1.2 channel — some electrophysiological measurements show overactivity, while others show underactivity. The result is a symptom profile that does not fit neatly into either the GOF or LOF category.
Children with mixed function variants may experience both epilepsy and neurodevelopmental features, and their responses to treatment can be less predictable. For families navigating a mixed function diagnosis, specialist involvement and individualized care planning are especially important. The SCN2A research community is actively working to better characterize these variants and their treatment implications.
The age at which symptoms — particularly seizures — first appear is one of the most informative clues about the underlying variant type. Seizures appearing within the first days or weeks of life most often reflect GOF variants. Seizures appearing after 3 months of age, or developmental and behavioral concerns emerging without prominent epilepsy, are more commonly associated with LOF or mixed function variants.
That said, timing alone does not determine mutation type. Genetic testing remains the only definitive way to identify the specific SCN2A variant your child carries and begin to understand its functional implications.
If your child has been diagnosed with an SCN2A-related disorder, or if you recognize these symptoms and have not yet received a genetic diagnosis, you are not alone — and there are steps you can take.
Every family navigating an SCN2A diagnosis deserves answers, community, and hope. The work to find them depends on your support. Please consider making a donation to help fund the research and resources that move us all forward.
Want to go further? Join the fight to stay connected to the latest SCN2A research and advocacy efforts, or contact us with any questions.
Medical Disclaimer
This content is provided for educational and informational purposes only and does not constitute medical advice. The information on this page is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Vlad Magdalin
